This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0407-19
V. Individual has been on Cymbalta (duloxetine) or Irenka (duloxetine) in the past 180 days (medication samples/ coupons/ discount cards are excluded from consideration as a trial);
   OR

VI. Individual had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of and inadequate response or intolerance to one of the following medications:
   A. Venlafaxine (immediate or extended release products); OR
   B. Buspirone; OR
   C. Escitalopram; OR
   D. Paroxetine; OR
   E. Individual is 7 -18 years of age;

OR

VII. Individual has a diagnosis of neuropathic pain associated with diabetic peripheral neuropathy; AND

VIII. Individual had a previously approved clinical prior authorization review through Anthem for Cymbalta (duloxetine) or Irenka (duloxetine) in the past year that has recently expired;
   OR

IX. Individual had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of and inadequate response or intolerance to one of the following medications:
   A. Tricyclic antidepressants (AACE 2015, AAFP 2010, ADA 2017, NICE 2013); OR
   B. Gabapentin (AACE 2015, ADA 2017, NICE 2013, AHFS, DRUGDex B, Ila); OR
   C. Venlafaxine (immediate or extended-release products) (AACE 2015, ADA 2017); OR
   D. Lyrica*

OR

X. Individual has a clinical diagnosis of Fibromyalgia (for example, based upon symptoms of widespread pain, typically reported in the muscles and joints, findings of “multiple tender points” in characteristic soft tissue locations, and any disorder that would otherwise explain the pain have been excluded); AND

XI. Individual had a previously approved clinical prior authorization review through Anthem for Cymbalta (duloxetine) or Irenka (duloxetine) in the past year that has recently expired;

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
CRX-ALL-0407-19
OR

XII. Individual meets ALL of the following criteria:
   A. Symptoms have been present at a similar level for at least 3 months; **AND**
   B. Individual has had a trial (medication samples/coupons/discount cards are
      excluded from consideration as a trial) of and inadequate response or
      intolerance to **two** of the following medications that are FDA approved or
      medically accepted for the treatment of fibromyalgia:
         1. Tricyclic antidepressants (CFCG 2012, EULAR 2016); **OR**
         2. Gabapentin (CFCG 2012); **OR**
         3. Cyclobenzaprine(CFCG 2012, EULAR 2016); **OR**
         4. Fluoxetine (CFCG 2012) or alternative selective serotonin reuptake
            inhibitor (SSRI) (CFCG 2012; **OR**
         5. Savella*; **OR**
         6. Lyrica*

OR

XIII. Individual has a diagnosis of chronic musculoskeletal pain (such as, chronic low back
      pain [CLBP] or chronic pain from osteoarthritis); **AND**

XIV. Individual had a previously approved clinical prior authorization through Anthem for
      Cymbalta (duloxetine) or Irenka (duloxetine) in the past year that has recently expired
      **OR**

XV. Individual has had a trial (medication samples/coupons/discount cards are excluded from
      consideration as a trial) of and inadequate response or intolerance to one of the following
      medications:
         A. Non-steroidal anti-inflammatory drug (NSAID) (individually or as part of a
            combination product); **OR**
         B. Acetaminophen (individually or as part of a combination product); **OR**
         C. Tramadol

Note: SNRI antidepressants have a black box warning for suicidal thoughts and behaviors. Antidepressants
increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term
studies. Use is not approved in the pediatric population. Individuals, who are started on antidepressant therapy,
should be monitored closely for worsening, and emergence of suicidal thoughts and behaviors. Monitoring should especially
occur during the initial few months of a course of therapy, or at times of dose changes, either
increases or decreases.

*Prior authorization may be required

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor
does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations
may apply.
CRX-ALL-0407-19
This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0407-19
This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare.  Note that market specific restrictions or transition-of-care benefit limitations may apply.
CRX-ALL-0407-19